{"id":34,"company":{"country":"CA","currency":"CAD","exchange":"AEQUITAS NEO EXCHANGE","ipo":"2018-01-05","marketCap":155.992,"name":"Cybin Inc","phone":"19087648385.0","outstanding":234.683,"symbol":"CYBN","website":"https://www.cybin.com","industry":"Pharmaceuticals"},"price":0.5303,"year":2023,"month":9,"day":23,"weekday":"Saturday","title":"Impact of Global Economic Conditions on Cybin Inc Stock's Value","date":"2023-09-23","url":"/posts/2023/09/23/CYBN","content":[{"section":"Positive Impact: Growth Potential","text":"Inflation and robust global economic conditions can signal a strong demand for goods and services, leading to higher revenues and profits for Cybin Inc. As the economy expands, Cybin may experience increased demand for its products, such as psychedelic medicines, which can positively impact its stock's value. Additionally, inflation can raise the prices of assets, including stocks, potentially leading to an increase in Cybin's stock price."},{"section":"Negative Impact: Cost Pressures","text":"Inflation can also lead to higher costs for Cybin Inc. Rising input costs, such as raw materials, labor, and borrowing costs, can erode profit margins and negatively impact the stock's value. If inflation outpaces the company's ability to increase prices, it may face challenges in maintaining profitability, potentially leading to a decline in its stock price."},{"section":"Positive Impact: Interest Rates","text":"Global economic conditions, including inflation, can influence interest rates set by central banks. Lower interest rates can stimulate economic growth and investment, benefitting companies like Cybin Inc. Reduced borrowing costs can allow the company to expand operations, invest in research and development, or acquire strategic assets, which can positively affect its stock's value."},{"section":"Negative Impact: Market Sentiment","text":"Uncertain or unfavorable global economic conditions, such as high inflation rates, can create market volatility and negatively affect investor sentiment. If investors perceive the economic conditions as risky or unstable, they may sell their Cybin Inc shares, leading to a decline in the stock's value. Additionally, global economic downturns can reduce investor confidence and appetite for risky assets, potentially impacting Cybin's stock price negatively."},{"section":"Neutral Impact: Market correlations","text":"The impact of global economic conditions on Cybin Inc's stock value can be influenced by market correlations. While inflation and economic factors can directly impact Cybin's fundamentals, the overall market sentiment and trends can also play a role. For example, during periods of overall market downturn, even if Cybin's fundamentals remain strong, its stock price may be influenced by broader market trends rather than solely economic conditions."},{"section":"Conclusion","text":"The impact of global economic conditions, including inflation, on Cybin Inc stock's value is multifaceted. Economic conditions can both positively and negatively affect the company. It is crucial for investors to consider various factors, including inflation rates, input costs, interest rates, and market sentiment, to form a balanced perspective on the potential impact of global economic conditions on Cybin Inc's stock value."}],"tags":["stock","Long","Pharmaceuticals"],"news":[{"category":"company","date":1695978120,"headline":"Psychedelic drugs market to break $7B in 2029 led by these 3 meds","id":122863025,"image":"","symbol":"CYBN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3138619509"},{"category":"company","date":1695897660,"headline":"Here's What You Missed in Cannabis, Psychedelics This Week","id":122834633,"image":"","symbol":"CYBN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3137050471"},{"category":"company","date":1695814200,"headline":"Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder","id":122828357,"image":"https://media.zenfs.com/en/business-wire.com/d4b2f119e48ddd692ce4999c926affbb","symbol":"CYBN","publisher":"Yahoo","summary":"TORONTO, September 27, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (\"Cybin\" or the \"Company\"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, commends Small Pharma Inc. (\"Small Pharma\"), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, on its positive safety, tolerability and efficacy data from its Phase Ib study explo","url":"https://finance.yahoo.com/news/small-pharma-reports-positive-top-113000241.html"},{"category":"company","date":1695797160,"headline":"Cybin acquisition of Small Pharma to close in Q4","id":122817010,"image":"","symbol":"CYBN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3135006967"},{"category":"company","date":1695796800,"headline":"Cybin: Small Pharma data demonstrate  efficacy/safety of DMT with SSRIs","id":122817011,"image":"","symbol":"CYBN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3135000517"},{"category":"company","date":1695731040,"headline":"Psychedelics research amendments advance in House committee","id":122783328,"image":"","symbol":"CYBN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133730667"},{"category":"company","date":1695727800,"headline":"Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial","id":122784271,"image":"https://media.zenfs.com/en/business-wire.com/1c7f7ff198f3a9a85fb840724a191d06","symbol":"CYBN","publisher":"Yahoo","summary":"TORONTO, September 26, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (\"Cybin\" or the \"Company\"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced an agreement with Fluence, a leading continuing education organization in psychedelic therapy, to support the streamlining and scaling of Cybin’s EMBARK facilitator training program in preparation for a multi-site, global Ph","url":"https://finance.yahoo.com/news/cybin-announces-agreement-fluence-support-113000727.html"},{"category":"company","date":1695717240,"headline":"Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More","id":122779685,"image":"","symbol":"CYBN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133441924"},{"category":"company","date":1695712500,"headline":"Cybin in pact to support training in Phase 3 psychedelic trial","id":122817015,"image":"","symbol":"CYBN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133353338"},{"category":"company","date":1695710040,"headline":"Cybin announces agreement with Fluence to support scaling of Embark training","id":122817016,"image":"","symbol":"CYBN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133314134"},{"category":"company","date":1695696300,"headline":"Cybin And Fluence Partner To Support EMBARK Training For Phase 3 CYB003 Trial For Depression","id":122817017,"image":"","symbol":"CYBN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133921455"},{"category":"company","date":1695692340,"headline":"Depression Relief: Possible Therapy Boost With DMT \u0026 SSRIs, Per Small Pharma Clinical Results","id":122817018,"image":"","symbol":"CYBN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133830807"},{"category":"company","date":1695641400,"headline":"Cybin to Participate in the Cantor Global Healthcare Conference","id":122758309,"image":"https://media.zenfs.com/en/business-wire.com/65f24b1c7e6228b2619d57e98544628d","symbol":"CYBN","publisher":"Yahoo","summary":"TORONTO, September 25, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (\"Cybin\" or the \"Company\"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Chief Executive Officer of Cybin, and George Tziras, Chief Executive Officer of Small Pharma Inc., will participate in a panel discussion titled \"Emerging Therapeutic Candidates for Mental Health\"","url":"https://finance.yahoo.com/news/cybin-participate-cantor-global-healthcare-113000750.html"},{"category":"company","date":1695636600,"headline":"Are These Industries Worth Buying Penny Stocks In?","id":122757830,"image":"https://pennystocks.com/wp-content/uploads/2021/12/top-penny-stocks-to-buy-now-4.jpg","symbol":"CYBN","publisher":"PennyStocks","summary":"Can these industries help you to profit with penny stocks?","url":"https://pennystocks.com/featured/2023/09/25/are-industries-worth-buying-penny-stocks/"},{"category":"company","date":1695564480,"headline":"3 Tips for Trading Options With Penny Stocks","id":122750295,"image":"https://pennystocks.com/wp-content/uploads/2021/07/top-penny-stocks-to-buy-right-now.jpg","symbol":"CYBN","publisher":"PennyStocks","summary":"Use these tips to trade options with penny stocks","url":"https://pennystocks.com/featured/2023/09/24/3-tips-trading-options-penny-stocks/"},{"category":"company","date":1695330000,"headline":"Cybin Announces Date of Annual and Special Meeting of Shareholders","id":122715277,"image":"https://media.zenfs.com/en/business-wire.com/2e68c32cd028d4b012b535cb36a616eb","symbol":"CYBN","publisher":"Yahoo","summary":"TORONTO, September 21, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (\"Cybin\" or the \"Company\"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that its 2023 Annual and Special Meeting of Shareholders will be held virtually on Thursday, October 12, 2023 at 1:00 p.m. ET.","url":"https://finance.yahoo.com/news/cybin-announces-date-annual-special-210000699.html"},{"category":"company","date":1695295800,"headline":"Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder","id":122699391,"image":"https://media.zenfs.com/en/business-wire.com/124910a7f2f9d729401616a5d6632e29","symbol":"CYBN","publisher":"Yahoo","summary":"TORONTO, September 21, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (\"Cybin\" or the \"Company\"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that it has completed enrollment in its Phase 2 study of CYB003, a proprietary deuterated psilocybin analog program being developed for the potential treatment of major depressive disorder (\"MDD\"). All participants in","url":"https://finance.yahoo.com/news/cybin-completes-enrollment-phase-2-113000729.html"},{"category":"company","date":1695287220,"headline":"Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression","id":122725962,"image":"","symbol":"CYBN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3127938586"},{"category":"company","date":1695278220,"headline":"Cybin completes enrollment in CYB003 study","id":122701334,"image":"","symbol":"CYBN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3126775542"},{"category":"company","date":1695194580,"headline":"Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket","id":122680331,"image":"","symbol":"CYBN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3125172387"},{"category":"company","date":1695106920,"headline":"Why Elutia Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket","id":122658365,"image":"","symbol":"CYBN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3123479967"},{"category":"company","date":1695104940,"headline":"Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday","id":122658496,"image":"","symbol":"CYBN","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3123446940"},{"category":"company","date":1695053820,"headline":"Psychedelic stock jumps as Steve Cohen’s Point72 snaps up shares","id":122848573,"image":"https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg","symbol":"CYBN","publisher":"MarketWatch","summary":"Shares of Cybin Inc., a developer of psychedelic therapies, finished 38.5% higher on Monday after billionaire investor and New York Mets owner Steve Cohen’s...","url":"https://www.marketwatch.com/story/psychedelic-stock-jumps-as-steve-cohens-point72-snaps-up-shares-4ad3ee71"},{"category":"company","date":1695003180,"headline":"Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R\u0026D, Blake Mycoskie's $100M Pledge Update","id":122646745,"image":"","symbol":"CYBN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3122321780"},{"category":"company","date":1694833500,"headline":"With ecstasy a potential PTSD therapy, psychedelic treatments could take off","id":122630038,"image":"","symbol":"CYBN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3120259289"}]}